Polycystic ovary syndrome is no longer called polycystic ovary syndrome.
As of today, a landmark consensus study published in The Lancet has officially renamed the condition to polyendocrine metabolic ovarian syndrome, or PMOS. Over 22,000 clinicians and patients across 11 years of global consultation arrived at this conclusion: the old name was not just outdated. It was misleading. And it was shaping how providers thought about the condition in ways that held patients back.
I want to be direct about something: we have been teaching this.
For years, inside the Master Course, I have stood in front of providers and said the same thing this Lancet paper is now saying with a new acronym. PCOS is not an ovarian condition. It is a metabolic and endocrine condition that happens to show up in the ovaries. The cysts are not the story. The metabolism is the story. The hormones are the story. The gut is the story. And the old name made it almost impossible for providers to see that clearly.
Today, 22,000 clinicians and patients, and one of the most respected journals in the world, caught up to the physiology. That matters. Not because being early is a trophy. But because every provider who already learned this framework through HRTU is now standing on ground that the rest of medicine just recognized as solid.
What Changed and Why It Matters
The term “polycystic ovary syndrome” implied that the condition was primarily gynecological. Ovarian cysts were the defining feature. The ovaries were the problem.
Except they were not.
Many patients diagnosed with PCOS do not have ovarian cysts at all. And among those who do, the cysts are a downstream finding, not the cause. The name pointed providers toward the wrong organ and the wrong mechanism. It fragmented care across specialties. It delayed diagnosis. And it created a clinical blind spot: providers treated the surface presentation while the metabolic engine underneath kept running unchecked.
The new name, polyendocrine metabolic ovarian syndrome, corrects that. It tells clinicians three things the old name never did.
| PCOS (OLD) | PMOS (NEW) | |
| Name | Polycystic Ovary Syndrome | Polyendocrine Metabolic Ovarian Syndrome |
| Focus | Ovarian cysts / gynecology | Multi-system endocrine + metabolic condition |
| Primary organ | Ovaries | Multiple axes (thyroid, adrenals, ovaries, insulin) |
| Metabolic role | Downstream complication | Central to the condition from the start |
| Clinical framing | Fertility-first | Lifelong metabolic condition |
| Diagnostic lens | Rotterdam criteria only | Mechanism-based endocrine evaluation |
First, this is a polyendocrine condition. Multiple hormonal axes are involved. Not just the ovaries. Not just androgens. The thyroid, the adrenals, insulin signaling, and the interplay between estrogen, progesterone, and cortisol are all part of the picture.
Second, this is a metabolic condition. The metabolic dysfunction is not a complication of PMOS. It is central to it. Insulin resistance, mitochondrial inefficiency, and disrupted energy metabolism are not downstream effects that show up later. They are woven into the mechanism from the beginning.
Third, the ovaries are involved, but they are not the origin. Retaining “ovarian” in the name acknowledges the reproductive features without reducing the entire condition to a single organ.
Polyendocrine. Multiple hormonal axes are involved. Not just the ovaries.Not just androgens. The thyroid, the adrenals, insulin signaling, and theinterplay between estrogen, progesterone, and cortisol are all part of thepicture.
Metabolic. The metabolic dysfunction is not a complication of PMOS. It is central to it. Insulin resistance, mitochondrial inefficiency, and disrupted energy metabolism are not downstream effects that show up later. They are woven into the mechanism from the beginning.
Ovarian. Retaining “ovarian” in the name acknowledges the reproductive features without reducing the entire condition to a single organ.
We Have Been Here Before. This Is How Medicine Moves.
If you have been through Module 4 of the Master Course, today probably felt less like news and more like recognition.
Because here is what I teach in that module, and what I have been saying on the podcast, in the emails, and on every stage I have stood on for years: PCOS is not an androgen problem. It never was.
It is driven by relative estrogen dominance layered on sluggish detoxification. Environmental estrogens accumulate. Gut dysfunction, specifically elevated beta-glucuronidase activity, cleaves conjugated estrogen and sends it back into circulation. The liver’s phase two conjugation pathways are overwhelmed. Progesterone is suppressed. Thyroid function is compromised. And the metabolic machinery that should be producing clean energy through oxidative phosphorylation shifts toward glycolysis, the inefficient, inflammatory, stress-driven pathway.
That is the metabolic foundation. And the new name finally reflects it.
From the HRTU Master Course.
I remember the first time I said “PCOS is not about the ovaries” in a room full of providers. Some of them looked at me like I had lost the plot. But here is the thing about physiology: it does not care about convention. It does not care what the textbook said in 2010. The mechanism is the mechanism. And when you trace this condition back to its metabolic roots, the ovaries are a stop along the way, not the starting point.
The word “polyendocrine” in the new name validates what we cover across the first five modules of the Master Course: hormones do not operate in isolation. Estrogen dominance does not exist without thyroid involvement. Cortisol dysregulation does not happen without downstream effects on progesterone and testosterone. Metabolic dysfunction does not stay metabolic. It becomes endocrine. It becomes reproductive. It becomes neurological. The Big Five metabolic disruptors I teach, estrogen as a class, serotonin, cortisol, polyunsaturated fatty acids, and endotoxin, are exactly the interconnected system that the old name failed to capture.
The word “metabolic” puts energy metabolism where it belongs: at the center. This is the thesis that runs through every module of the Master Course. Hormone replacement therapy is a metabolic intervention, not a symptom management tool. When mitochondria fail to produce adequate energy via oxidative phosphorylation, cellular structure degrades. Function follows. Disease follows. The symptoms patients present with, irregular cycles, weight gain, mood disruption, are not the condition. They are the evidence of disrupted energy production.
That is not a fringe position. As of today, it is a Lancet-published one.
What This Means for Providers Right Now
I want to speak to two groups of providers reading this.
If you are already practicing with a metabolic framework, if you came through the Master Course or arrived at this understanding through your own clinical work, today is validation. You were not ahead of your time. You were on time. The rest of the field is catching up. That community of providers who chose to learn the physiology before the guidelines caught up, that is a movement. It is thousands of clinicians deep now, and it is growing because the results in the room speak louder than any consensus paper.
If you are new to this way of thinking, if you have been treating PCOS the way you were taught and something has not felt right, this rename is your invitation. Not to feel behind. To recognize that the discomfort you have been carrying, the sense that the standard framework is incomplete, was accurate. It was always accurate. And there is a path forward.
Here is what the rename should change in practice.
- Stop treating PMOS as a fertility-only concern.The old name funneled patients toward reproductive endocrinology and stopped there. PMOS is a lifelong metabolic condition with cardiovascular, neurological, and endocrine consequences that extend far beyond the reproductive years.
- Reassess the role of oral contraceptives. The reflexive prescription of combined oral contraceptives for PCOS has been the standard of care for decades. But oral contraceptives suppress the entire hypothalamic-pituitary-ovarian axis. They eliminate endogenous progesterone production. The synthetic progestins they contain cannot convert to allopregnanolone, the neurosteroid that modulates GABA and stabilizes mood. If PMOS is a metabolic and endocrine condition, suppressing the endocrine system is not a treatment. It is the management of a lab value at the cost of the underlying physiology.
- Think about endotoxin. This is one of the most underappreciated contributors to what we now call PMOS. Lipopolysaccharides from gram-negative bacteria escape the gut into systemic circulation. They trigger inflammatory cascades via TLR-4. They suppress metabolism. They increase cortisol, prolactin, and estrogen while decreasing progesterone, pregnenolone, and testosterone. In the peritoneal cavity, endotoxin attacks nearby organs, including the uterus and ovaries, driving the estrogen dominance and proliferation that define this condition. Gut health is not adjacent to PMOS. It is foundational.
- Address thyroid early and thoroughly. The thyroid hormone directly impacts mitochondrial function. It enhances oxidative capacity. It increases ATP production. If thyroid is not addressed, metabolic optimization is incomplete, and the hormonal cascade that feeds PMOS continues unchecked. ATSH of 4.0 is within “normal” range. It is not optimal. And for a patient with PMOS, it may be the first domino.
- Consider progesterone as more than endometrial protection. In the context of PMOS, progesterone is not just a uterine safeguard. It is a metabolic counterbalance to estrogen dominance. It converts to allopregnanolone, supporting GABA activity and nervous system stability. It opposes the proliferative effects of unopposed estrogen. Prescribing progesterone only for endometrial protection in a patient with PMOS is working with half the picture.
The Bigger Shift Happening in Medicine
This rename is not an isolated event. It is part of something larger, and if you have been paying attention, you have seen it building.
Medicine is slowly moving from symptom-based labels toward mechanism-based understanding. The same shift is happening with depression, which is increasingly recognized as a physiological state, a symptom of metabolic and hormonal disruption, rather than a primary psychiatric diagnosis. It is happening with metabolic syndrome. It happened when the WHI data was finally reexamined and the distinction between bioidentical and non-identical hormones started to matter publicly.
And it is happening here. Right now. With this rename.
I have said this before and I will say it again: the providers who are willing to learn the mechanism, to sit with the complexity instead of reaching for the protocol, are the ones who will define the next era of this field. That is what we built HRT University around. Not a set of dosing templates. A way of thinking.
For providers, this matters because it changes the question you ask in the room. The old question was: does this patient meet the Rotterdam criteria for PCOS? The better question is: what is happening metabolically and endocrinologically that is producing these findings?
That second question leads to better treatment. It leads to progesterone, thyroid support, gut repair, dietary intervention to reduce estrogenic load, and bioidentical hormone therapy as a metabolic intervention. It leads to the kind of clinical clarity that does not collapse when a patient does not follow the script.
The providers in our community already know this. They are already asking the second question. They have been for years. And their patients are better for it.
Where to Go From Here
The Lancet study outlines a three-year transition period for the PMOS terminology, with full adoption expected in the 2028 international guideline update. The name will change in coding systems, in clinical guidelines, and eventually in the way patients are counseled.
But the physiology has not changed. It was always metabolic. It was always endocrine. It was always more than the ovaries. We did not need a Lancet paper to know that. We needed patients, clinical reasoning, and the willingness to follow the mechanism wherever it led.
If you want to understand the framework behind what the new name is pointing toward, this is exactly what we built the Master Course to teach. Module 4 addresses PMOS (formerly PCOS) through the lens of estrogen dominance, endotoxin, and metabolic foundations. Module 1 builds the metabolic framework that makes the rest of it make sense. Module 5 addresses the thyroid piece that no conversation about PMOS is complete without.
And beyond the course, there is a community. Thousands of providers who have gone through this material and come out the other side with a clarity they did not have before. They are in the membership. They are at HRTU Live events. They are using Pearl to think through cases in real time. They are the movement that this name change just validated.
The name changed today. The framework we teach did not need to. And neither did the providers who already learned it.
Frequently Asked Questions
What is the new name for PCOS?
PCOS has been renamed PMOS, which stands for polyendocrine metabolic ovarian syndrome, following a global consensus study published in The Lancet in 2026.
Why was PCOS renamed to PMOS?
The name was changed because “polycystic ovary syndrome” was misleading. Many patients do not have ovarian cysts, and the condition involves multiple endocrine and metabolic systems, not just the ovaries.
When will PMOS replace PCOS officially?
The transition period is three years, with full adoption of PMOS expected in the 2028 international guideline update.
What does polyendocrine metabolic ovarian syndrome mean?
The name reflects three key aspects of the condition: it involves multiple hormonal (polyendocrine) systems, it is fundamentally a metabolic disorder, and the ovaries are involved but are not the sole or primary origin.
How should providers treat PMOS differently than PCOS?
The rename encourages providers to move beyond treating PMOS as a fertility concern and instead address the underlying metabolic and endocrine dysfunction, including thyroid optimization, progesterone therapy, gut health, and estrogen metabolism support.
HRT University is a physiology-first clinical education company founded by Nico Misleh, NP. The Master Course is jointly accredited and offers 30 CE credits across six modules covering metabolic foundations, male and female HRT, advanced female endocrinology, thyroid optimization, and adjunct hormones.
